Does magnesium have a role in the treatment of patients with coronary artery disease?

American Journal of Cardiovascular Drugs

Volumn 3, Issue 4, 2003, Pages 231-239

  Shechter, Michael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; FREE RADICAL; ISOPRENALINE; LIDOCAINE; MAG OX; MAGNESIUM; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; MAGNESIUM OXIDE; MAGNESIUM SULFATE; MAGNOSOLV; NITROPRUSSIDE SODIUM; OXYGEN; PLACEBO;

ACUTE HEART INFARCTION; BLOOD VESSEL TONE; CALCIUM TRANSPORT; CELL DEATH; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG COST; DRUG EXCRETION; DRUG INDICATION; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG USE; ELDERLY CARE; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; HYPOMAGNESEMIA; LIPID METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINUS BRADYCARDIA; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TORSADE DES POINTES; VASCULAR RESISTANCE;

AGED; ANIMALS; ANTICOAGULANTS; HUMANS; LIPID METABOLISM; MAGNESIUM; MAGNESIUM DEFICIENCY; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY;

EID: 0042286500     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303040-00001     Document Type: Review

References (104)

1. Shechter M, Kaplinsky E, Rabinowitz B. The rationale of magnesium supplementation in acute myocardial infarction: a review of the literature. Arch Intern Med 1992; 152: 2189-96
2. Centers for Disease Control and Prevention. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase I, 1988-91: advance data from vital and health statistics; no 258. Hyattsville (MD): National Center for Health Statistics, 1994: 1-28
3. Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. J Am Coll Nutr 1986; 5 (4): 399-414
4. Seelig MS. The requirement of magnesium by normal adult. Am J Clin Nutr 1964; 6: 342-90
5. Seelig MS. Cardiovascular consequences of magnesium deficiency and loss: pathogenesis, prevalence and manifestations: magnesium and chloride loss in refractory potassium repletion. Am J Cardiol 1989; 63: 4G-21G
6. Lichton IJ. Dietary intake levels of requirements of Mg and Ca for different segments of the US population. Magnesium 1989; 8: 117-23
7. Peterson DR, Thompson DJ, Nam JM. Water hardness, arteriosclerotic heart disease and sudden death. Am J Epidemiol 1970; 92: 90-3
8. Shaper AG. Soft water, heart attacks, and stroke. JAMA 1974; 230: 130-1
9. Anderson TW, Neri LC, Schreiber GB, et al. Ischemic heart disease, water hardness and myocardial magnesium. CMAJ 1975; 113: 199-203
10. Chipperfield B, Chipperfield JR. Heart-muscle magnesium, potassium, and zinc concentrations after sudden death from heart disease. Lancet 1973; II: 293-5
11. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480-90
12. Ford ES. Serum magnesium and ischemic heart disease: findings from national sample of US adults. Int J Epidemiol 1999; 28: 645-51
13. GUSTO Investigators. GUSTO: an international trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
14. Althouse R, Maynard C, Cerguiera MD, et al. The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial. Am J Cardiol 1990; 66: 1298-303
15. Behar S, Abinader E, Caspi A, et al. Frequency of use of thrombolytic therapy in acute myocardial infarction in Israel. Am J Cardiol 1991; 68: 1291-4
16. Behar S, Gilat D, Reicher-Reiss H, et al. Myocardial infarction in patients older than 75 years of age: the short- and long-term prognosis in 653 consecutive patients. Cardiol Elderly 1993; 1: 103-11
17. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995; 91: 1659-68
18. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22
19. Montague TJ, Ikuta RM, Wong RY, et al. Comparison of risk and pattern of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989). Am J Cardiol 1991; 68: 843-7
20. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarction treated with thrombolysis. N Engl J Med 1993; 329: 1442-8
21. Kirklin JW, Akins CW, Blackstone EH, et al. ACC/AHA guidelines and indications for coronary artery bypass graft surgery: a report of the American College of Cardiology/ American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Circulation 1991; 83: 1125-72
22. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18: 657-62
23. Ball S, Corrao J, Gore J, et al. Patients ineligible for thrombolytic therapy: the GUSTO acute myocardial infarction census log. Circulation 1993; 88: I-60
24. Seelig MS. Possible roles of magnesium in disorders of the aged. In: Regelson W, Sinex FM, editors. Intervention in the aging process: part A. quantitation, epidemiology, clinical research. New York: AR Liss Inc, 1983: 279-305
25. Johansson G. Magnesium metabolism: studies in health, primary hyperparathyroidism and renal stone disease. Scand J Urol Nephrol 1979; 51: 1-47
26. Shechter M, Kaplinsky E, Rabinowitz B. Review of clinical evidence: is there a role for supplemental magnesium in acute myocardial infarction in high-risk populations (patients ineligible for thrombolysis and the elderly)? Coron Artery Dis 1996; 7: 352-8
27. Dickens BF, Weglicki WB, Li YS, et al. Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells. FEBS Lett 1992; 311: 187-91
28. Rasmussen HS, Meier K, Larsen OG, et al. Hemodynamic effects of intravenous administered magnesium in patients with ischemic heart disease. Int J Cardiol 1988; 11: 824-8
29. Altura BM, Altura BT. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. Magnesium 1985; 4: 245-71
30. Rasmussen HS, Aurup P, Goldstein K, et al. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. Arch Intern Med 1989; 149: 1050-3
31. Hwang DL, Yen CF, Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertens 1992; 5: 700-6
32. Gawaz M, Ott I, Reininger AJ, et al. Effects of magnesium on platelet aggregation and adhesion: magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb Haemost 1994; 72: 912-8
33. Nadler JL, Goodson S, Rude RK. Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension 1987; 9: 379-83
34. Shechter M, Bairey Merz CN, Rude RK, et al. Low intracellular magnesium levels promote platelet-dependent thrombus formation in patients with coronary artery disease. Am Heart J 2000; 140: 212-8
35. Shechter M, Bairey Merz CN, Paul-Labrador M, et al. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol 1999, 6
36. Vormann J, Fiscer G, Classen HG, et al. Influence of decreased and increased magnesium supply on cardiotoxic effects of epinephrine in rats. Arzneimittel Forschung 1983; 33: 205-10
37. Atar D, Serebruany V, Poulton J, et al. Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 1994; 24: 603-11
38. Herzog WR, Atar D, Mak IT, et al. Magnesium deficiency prolongs myocardial stunning in an open-chest swine model. Int J Cardiol 1995; 47: 105-15
39. Rasmussen HS, McNair P, Norregard P, et al. Magnesium infusion in acute myocardial infarction. Lancet 1986; I: 234-6
40. Rasmussen HS, Gronbaek M, Cintin C, et al. One-year rate in 270 patients with suspected acute myocardial infarction, initially treated with intravenous magnesium or placebo. Clin Cardiol 1988; 11: 377-81
41. Smith LF, Heagerty AM, Bing RF, et al. Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality. Int J Cardiol 1986; 12: 175-80
42. Abraham AS, Rosenman D, Meshulam Z, et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987; 147: 753-5
43. Ceremuzynski L, Jurgiel R, Kulakowski P, et al. Threatening arrhythmias in acute myocardial infarction are prevented by intravenous magnesium sulfate. Am Heart J 1989; 118: 1333-4
44. Shechter M, Hod H, Marks N, et al. Beneficial effect of magnesium sulfate in acute myocardial infarction. Am J Cardiol 1990; 66: 271-4
45. Shechter M, Hod H. Magnesium therapy in aged patients with acute myocardial infarction. Magnesium Bull 1991; 13: 7-9
46. Feldstedt M, Boesgaard S, Bouchelouche P, et al. Magnesium substitution in acute ischaemic heart syndromes. Eur Heart J 1991; 12: 1215-8
47. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-8
48. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials. BMJ 1991; 303: 1499-503
49. Woods KL, Fletcher S. Long term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-9
50. Shechter M, Hod H, Chouraqui P, et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 321-3
51. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
52. du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated heart by agents altering calcium flux at reperfusion. Circ Res 1992; 70: 960-7
53. Leor J, Kloner RA. An experimental model examining the role of magnesium in the therapy of acute myocardial infarction. Am J Cardiol 1995; 75: 1292-3
54. Seelig MS, Elin RJ. Reexamination of magnesium infusions in myocardial infarction. Am J Cardiol 1995; 76: 172-3
55. Antman EM. Randomized trials of magnesium in acute myocardial infarction: big numbers do not tell the whole story. Am J Cardiol 1995; 75: 391-3
56. Galloe AM, Rasmussen HS, Jorgensen LN, et al. Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. BMJ 1993; 307: 585-7
57. Shechter M, Hod H, Rabinowitz B, et al. Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium. Circulation 2001; 104: II-744-5
58. MAGIC Steering Committee: Rationale and design of the Magnesium in Coronaries (MAGIC) Study: a clinical trial to reevaluate the efficacy of early administration of magnesium in acute myocardial infarction. Am Heart J 2000; 139: 10-4
59. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J 1984; 108: 188-93
60. Holyrode MI, Robertson SP, Johnson JD, et al. The calcium and magnesium binding sites on cardiac troponin and their role in the regulation of myofibrillar adenosine triphosphatase. J Biol Chem 1980; 255: 11688-91
61. Sordahl LA. Effects of magnesium on initial rates of calcium uptake and release of heart mitochondria. Arch Biochem Biophys 1975; 167: 104-7
62. Mroczek WJ, Lee WR, Davidov ME. Effect of magnesium sulfate on cardiovascular hemodynamics. Angiology 1977; 28: 720-4
63. Cotton DB, Gonik B, Dorman KF. Cardiovascular alterations in severe pregnancy-induced hypertension: acute effects of intravenous magnesium sulfate. Am J Obstet Gynecol 1984; 148: 162-5
64. Altura BM. Magnesium neurohypophyseal hormone interactions in contraction of vascular smooth muscle. Am J Physiol 1975; 228: 1615-20
65. Altura BM, Altura BT, Corella A. Magnesium deficiency-induced spasms of umbilical vessels: relation to preeclampsia, hypertension, growth retardation. Science 1983; 221: 376-8
66. Altura BM, Altura BT. Vascular smooth muscle and prostaglandins. Fed Proc 1976; 35: 2360-6
67. Askar AD, Mustafa SJ. Role of magnesium in the relaxation of coronary arteries by adenosine. Magnesium 1983; 2: 17-25
68. Whelton PK, Klay MJ. Magnesium and blood pressure: review of the epidemiologic and clinical trial experience. Am J Cardiol 1989; 63: 26G-30G
69. Mizushima S, Cappuccio FP, Nichols R, et al. Dietary magnesium intake and blood pressure: a qualitative overview of the observational studies. J Hum Hypertens 1998 Jul; 12 (7): 447-53
70. Kugiyama K, Yasue H, Okumara K, et al. Suppression of exercise-induced angina by magnesium sulfate in patients with variant angina. J Am Coll Cardiol 1988; 12: 1177-83
71. Zwillinger L. Uber die Magnesiumwirkung auf das Herz. Klin Wochenschr 1935; 14: 1329-433
72. Chadda KD, Lichstein E, Gupta P. Hypomagnesemia and refractory cardiac arrhythmia in a nondigitalized patient. Am J Cardiol 1973; 31: 98-100
73. Beller GA, Hood Jr WB, Abelmann WH, et al. Correlation of serum magnesium levels and cardiac digitalis intoxication. Am J Cardiol 1974; 33: 225-9
74. Tzivoni D, Keren A. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol 1990; 65: 1397-9
75. Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsade de pointes. Am J Cardiol 1984; 53: 528-30
76. Lloyd T, Iseri MD, Fairshter R, et al. Magnesium suppression of exercise-induced angina by magnesium sulfate in patients with variant angina. J Am Coll Cardiol 1988; 12: 1177-83
77. Altura BM, Altura BT. Magnesium ions and contraction of vascular smooth muscles: relationship to some vascular diseases. Fed Proc 1981; 40: 2672-4
78. Lucas MJ, Veveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for prevention of eclampsia. N Engl J Med 1995; 333: 201-5
79. Whang R, Welt LC. Observations in experimental magnesium depletion. Clin Invest 1963; 42: 305-13
80. Lloyd T, Iseri MD, Fairshter R, et al. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J 1985; 110: 789-94
81. Arsenian MA. Magnesium and cardiovascular disease. Prog Cardiovasc Dis 1993; 35: 271-310
82. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. An international consensus on science: The American Heart Association in collaboration with the International Liaison Committee on Resuscitation (ILCOR). Circulation 2000; 102: I-147-50
83. Ouchi Y, Tabata RE, Stergiopoulos K, et al. Effect of dietary magnesium on development of atherosclerosis in cholesterol fed rabbits. Arteriosclerosis 1990; 10: 732-7
84. Rayssiguier Y, Guex E, Weiser D. Effect of magnesium deficiency on lipid metabolism in rats fed a high carbohydrate diet. J Nutr 1981; 111: 1876-83
85. Luthringer C, Rayssiguier Y, Gueux E, et al. Effect of moderate magnesium deficiency on serum lipids, blood pressure and cardiovascular reactive in normotensive rats. Br J Nutr 1988; 59: 243-50
86. Davis WH, Leary WP, Reyes AH. Monotherapy with magnesium increases abnormally low high density lipoprotein cholesterol: a clinical assay. Curr Ther Res 1984; 36: 341-4
87. Niemela JE, Csako G, Bui MN, et al. Gender-specific correlation of platelet ionized magnesium and serum low-density cholesterol concentrations in apparently healthy subjects. J Lab Clin Med 1997; 129: 89-96
88. Greville GD, Lehmann H. Cation antagonism in blood coagulation. J Physiol 1943; 103: 175-84
89. Schnitzler B. Thromboseprophylaxe mit Magnesium. Munch Med Wochenschr 1957; 99: 81-4
90. Anstall HB, Huntsman RG, Lehmann H, et al. The effect of magnesium on blood coagulation in human subjects. Lancet 1959; I: 814-5
91. Adams JH, Mitchel JRA. The effect of agents which modify platelet behavior and of magnesium ions on thrombus formation in vivo. Thromb Haemost 1979; 42: 603-10
92. Frandsen NJ, Winther K, Pedersen F, et al. Magnesium and platelet function: In vivo influence on aggregation and alpha-granule release in healthy volunteers. Magnesium Bull 1995; 17: 37-40
93. Born GVR, Cross GP. Effect of inorganic ions and plasma proteins on the aggregation of blood platelets by adenosine diphosphate. J Physiol 1964; 170: 397-414
94. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res 1996; 83: 341-9
95. Badimon L, Badimon JJ, Galvez A, et al. Influence of arterial damage and wall shear rate on platelet formation: ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-20
96. Ravn HB, Kristensen SD, Hjortdal VE, et al. Early administration of intravenous magnesium inhibits arterial thrombus formation. Arterioscler Thromb Vasc Biol 1997; 17: 3620-5
97. Phillips DR, Charo IF, Prise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43
98. Shechter M, Sharir M, Paul Labrador M, et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000; 102: 2353-8
99. Haigney MCP, Silver B, Tanglao E, et al. Noninvasive measurement of tissue magnesium and correlation with cardiac levels. Circulation 1995; 92: 2190-7
100. Pearson PJ, Evora PR, Seccombe JF, et al. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations. Ann Thorac Surg 1998; 65: 967-72
101. Shechter M, Paul-Labrador M, Rude RK, et al. Intracellular magnesium predicts functional capacity in patients with coronary artery disease. Cardiology. 1998; 90: 168-72
102. Shechter M, Bairey Merz CV, Stuehlinger HG, et al. Effects of oral magnesium therapy in exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. J Am Coll Cardiol 2003; 91: 517-21
103. Morton BC, Nair RC, Smith FM, et al. Magnesium therapy in acute myocardial infarction. Magnesium 1984; 3: 346-52
104. Magnesium in Coronaries (MAGIC) trial investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium Coronaries (MAGIC) trial: a randomized controlled trial. Lancet 2002; 360: 1189-96